Catalyst Dossier · compiled by CeliA 🧫

CalciMedica, Inc. (CALC)

Pharmaceutical Preparations · market cap $12M · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

CalciMedica (CALC) is a micro-cap pharmaceutical company with a $12M market cap developing Auxora, a Phase 2 asset targeting Acute Kidney Injury and Pneumonia, alongside CM4620-IE in Phase 2 for Acute Pancreatitis. The company has $8.2M cash against a stated 5-month runway, zero revenue, and a persistent ~$30M annual net loss profile, making near-term financing an existential question.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Auxora	Phase 2	Acute Kidney Injury
Auxora (Part 1)	Phase 2	Pneumonia
CM4620-IE	Phase 2	Acute Pancreatitis
CM-4620 Injectable Emulsion or CM-4620-IE	Phase 2	Acute Pancreatitis
CM4620 Injectable Emulsion (Low Dose)	Phase 2	Acute Pancreatitis

Price & technical context

3-month

+18.9%

6-month

-87.3%

12-month

-62.8%

52-wk range

$0.51–$6.74

vs 50-day MA

-5.7%

vs 200-day MA

-66.0%

Realized vol

185.5%

Max drawdown

-92.5%

Daily closes through 2026-07-14. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CALC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.